Pharmamarketeer

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

Venclexta

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose cytarabine as a treatment for newly-diagnosed acute myeloid leukaemia (AML) in patients at least 75 years old, or who have comorbidities that make the use of intensive induction chemotherapy inappropriate.

read more

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl